文献速递心境障碍

艾司西酞普兰而非裸盖菇素治疗抑郁时降低大脑对情绪刺激的反应

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression.
PubMed 文献 · Am J Psychiatry · 2025-05-07

该研究比较了裸盖菇素与艾司西酞普兰治疗重性抑郁对情绪面孔BOLD fMRI反应的影响。艾司西酞普兰组治疗后对各类情绪面孔的BOLD反应显著降低,裸盖菇素组无变化或轻度增加。尽管裸盖菇素组抑郁症状大幅改善,但其对大脑情绪反应性仅影响轻微。

要点

  • 艾司西酞普兰治疗后对情绪面孔的BOLD反应显著降低,裸盖菇素组无变化或轻度增加。
  • 艾司西酞普兰组对恐惧面孔的杏仁核反应降低,裸盖菇素组效应较小。
  • 裸盖菇素组抑郁症状大幅改善,但对情绪刺激的大脑反应性仅轻微影响。

核心结论

  • 尽管裸盖菇素组抑郁症状大幅改善,裸盖菇素治疗对大脑情绪刺激反应性仅影响轻微,而艾司西酞普兰治疗伴随情绪反应性降低。

研究设计与样本

  • 两组重性抑郁患者:一组(N=25;9女16男)接受两次25 mg裸盖菇素给药加6周每日惰性安慰剂,另一组(N=21;6女15男)接受6周艾司西酞普兰加两次1 mg非精神活性裸盖菇素给药。
  • 两组均接受同等心理支持:3小时准备、裸盖菇素给药后1次面对面整合会话及另外2次通过视频通话或电话进行的整合会话。
  • 治疗前及6周治疗后主要终点(裸盖菇素给药后3周)完成情绪面孔fMRI范式。

主要发现

  • 患者组(裸盖菇素vs艾司西酞普兰)与时间点(治疗前vs治疗后)在分布式皮层区域存在交互作用。
  • 事后组内分析显示,艾司西酞普兰组治疗后对所有类型情绪面孔的BOLD反应显著降低,裸盖菇素组无变化或轻度增加。
  • 杏仁核反应性分析显示,艾司西酞普兰组对恐惧面孔的反应降低,裸盖菇素组效应较小。

临床怎么用

  • SSRIs抗抑郁作用常伴随情绪反应性降低,而裸盖菇素治疗的抗抑郁机制可能不依赖此效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Psilocybin is an emerging intervention for depression that may be at least as effective as selective serotonin reuptake inhibitors (SSRIs), but effects of the two treatments on the neural correlates of emotional processing have never been directly compared. METHODS: The authors assessed neural responses to emotional faces using blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) in two groups with major depression. One group (N=25; 9 women and 16 men) received two dosing sessions with 25 mg psilocybin plus 6 weeks of daily inert placebo, and the second group (N=21; 6 women and 15 men) received 6 weeks of escitalopram plus two dosing sessions with a nonpsychoactive (placebo) dose of 1 mg psilocybin. Both groups had equal psychological support throughout: 3 hours of preparation, one in-person integration session following the psilocybin dosing sessions, and two further integration sessions conducted via video call or telephone. An emotional face fMRI paradigm was completed before treatment and at the 6-week posttreatment primary end point (3 weeks following psilocybin dosing sessions). RESULTS: Patient group (psilocybin versus escitalopram) interacted with time point (before versus after treatment) on a distributed set of cortical regions. Post hoc within-condition analyses showed that posttreatment BOLD responses to emotional faces of all types were significantly reduced in the escitalopram group, with no change or a slight increase in the psilocybin group. Analyses of amygdala responsivity showed a reduction of response to fearful faces in the escitalopram group, but lesser effects for the psilocybin group. CONCLUSIONS: Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wall MB, Demetriou L, Giribaldi B, et al. Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression. Am J Psychiatry. 2025. PMID: 40329640. doi:10.1176/appi.ajp.20230751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。